Previously, it was demonstrated that treatment of cutaneous T cell lymphoma (CTCL) cell lines (HH and Hut78) with a selective HDAC3 inhibitor caused a 50% reduction in DNA replication fork velocity and remarkable cell growth arrest [47]. Here, HDAC3 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.